Jazz Pharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

21.12.17	Jazz Pharmaceuticals Submits New Drug Application for Solriamfetol (JZP-110) for Excessive Sleepiness Associated with Narcolepsy and Obstructive Sleep Apnea (PR Newswire)
21.12.17	Jazz Pharmaceuticals Submits New Drug Application for Solriamfetol (JZP-110) for Excessive Sleepiness Associated with Narcolepsy and Obstructive Sleep Apnea (PR Newswire)
07.12.17	Jazz Pharmaceuticals to Present at the BMO Capital Markets Healthcare Conference (PR Newswire)
07.12.17	Jazz Pharmaceuticals to Present at the BMO Capital Markets Healthcare Conference (PR Newswire)
04.12.17	Jazz Pharmaceuticals Announces Appointment Of Daniel Swisher As President And Chief Operating Officer (PR Newswire)
04.12.17	Jazz Pharmaceuticals Announces Appointment Of Daniel Swisher As President And Chief Operating Officer (PR Newswire)
29.11.17	Ericsson : First 5G Life Campus to Open in Belgium (PR Newswire)
28.11.17	RealNetworks Announces Kontxt, a Next Generation Mobile Messaging Platform (PR Newswire)
28.11.17	RealNetworks Announces Kontxt, a Next Generation Mobile Messaging Platform (PR Newswire)
09.11.17	Jazz Pharmaceuticals Announces Participation in Three Upcoming Investor Conferences (PR Newswire)
09.11.17	Jazz Pharmaceuticals Announces Participation in Three Upcoming Investor Conferences (PR Newswire)
07.11.17	Jazz Pharmaceuticals Announces Third Quarter 2017 Financial Results (PR Newswire)
07.11.17	Jazz Pharmaceuticals Announces Third Quarter 2017 Financial Results (PR Newswire)
06.11.17	FDA Ruling On DVAX This Week, XNCR On Watch, It's Impressive But Early For AVXL (RTTNews)
03.11.17	Jazz Pharmaceuticals Submits Vyxeos™ Marketing Authorization Application to European Medicines Agency for Treatment of Certain Types of High-Risk Acute Myeloid Leukemia (PR Newswire)
03.11.17	Jazz Pharmaceuticals Submits Vyxeos™ Marketing Authorization Application to European Medicines Agency for Treatment of Certain Types of High-Risk Acute Myeloid Leukemia (PR Newswire)
01.11.17	Jazz Pharmaceuticals to Highlight Hematology Research at ASH 2017 Annual Meeting (PR Newswire)
01.11.17	Jazz Pharmaceuticals to Highlight Hematology Research at ASH 2017 Annual Meeting (PR Newswire)
24.10.17	Jazz Pharmaceuticals to Report 2017 Third Quarter Financial Results on November 7, 2017 (PR Newswire)
24.10.17	Jazz Pharmaceuticals to Report 2017 Third Quarter Financial Results on November 7, 2017 (PR Newswire)
12.09.17	Fortune Magazine Names Jazz Pharmaceuticals 78th Fastest Growing Company for 2017 (PR Newswire)
12.09.17	Fortune Magazine Names Jazz Pharmaceuticals 78th Fastest Growing Company for 2017 (PR Newswire)
07.09.17	New Drugs Approved In August (RTTNews)
01.09.17	Jazz Pharmaceuticals Announces Completion of Offering and Exercise in Full of Initial Purchasers' Option to Purchase Additional 1.50% Exchangeable Senior Notes due 2024 (PR Newswire)
01.09.17	Jazz Pharmaceuticals Announces Completion of Offering and Exercise in Full of Initial Purchasers' Option to Purchase Additional 1.50% Exchangeable Senior Notes due 2024 (PR Newswire)
30.08.17	Jazz Pharmaceuticals to Present at the Wells Fargo Securities Healthcare Conference (PR Newswire)
29.08.17	Biotech Stocks Facing FDA Decision In September (RTTNews)
29.08.17	Jazz Pharmaceuticals and ImmunoGen, Inc. Announce a Strategic Collaboration and Option Agreement to Develop and Commercialize Antibody-Drug Conjugate Products (PR Newswire)
29.08.17	Jazz Pharmaceuticals and ImmunoGen, Inc. Announce a Strategic Collaboration and Option Agreement to Develop and Commercialize Antibody-Drug Conjugate Products (PR Newswire)
25.08.17	Apttus Releases Intelligent Incentive Compensation Management Solution (PR Newswire)
18.08.17	Jazz Pharmaceuticals Announces Offering of $500 Million of 1.50% Exchangeable Senior Notes due 2024 (PR Newswire)
18.08.17	Jazz Pharmaceuticals Announces Offering of $500 Million of 1.50% Exchangeable Senior Notes due 2024 (PR Newswire)
17.08.17	Jazz Pharmaceuticals Announces Offering of $500 Million of Exchangeable Senior Notes due 2024 (PR Newswire)
17.08.17	Jazz Pharmaceuticals Announces Offering of $500 Million of Exchangeable Senior Notes due 2024 (PR Newswire)
11.08.17	Technical Snapshots for These Biotech Stocks -- ImmunoGen, Incyte, Infinity Pharma, and Jazz Pharma (PR Newswire)
08.08.17	Jazz Pharmaceuticals Announces Second Quarter 2017 Financial Results (PR Newswire)
08.08.17	Jazz Pharmaceuticals Announces Second Quarter 2017 Financial Results (PR Newswire)
04.08.17	DVAX Plunges On Delay In Approval, FDA Nod For ABBV's HCV Drug, ABIO On Radar (RTTNews)
04.08.17	FDA Oks Treatment For Certain Types Of Poor-prognosis Acute Myeloid Leukemia (RTTNews)
03.08.17	Jazz Pharmaceuticals Announces Webcast for Vyxeos Investor Update (PR Newswire)
31.07.17	PDL BioPharma to Announce Second Quarter 2017 Financial Results on August 3, 2017 (PR Newswire)
26.07.17	Jazz Pharmaceuticals and XL-protein GmbH Enter Into a License Agreement on PASylation® Technology to Develop Long-Acting Asparaginase Product Candidates (PR Newswire)
26.07.17	Jazz Pharmaceuticals and XL-protein GmbH Enter Into a License Agreement on PASylation® Technology to Develop Long-Acting Asparaginase Product Candidates (PR Newswire)
24.07.17	Jazz Pharmaceuticals to Report 2017 Second Quarter Financial Results on August 8, 2017 (PR Newswire)
24.07.17	Jazz Pharmaceuticals to Report 2017 Second Quarter Financial Results on August 8, 2017 (PR Newswire)
06.06.17	Jazz Pharmaceuticals Presents JZP-110 Data in Patients with Excessive Sleepiness Associated with Obstructive Sleep Apnea (PR Newswire)
06.06.17	Jazz Pharmaceuticals Presents JZP-110 Data in Patients with Excessive Sleepiness Associated with Obstructive Sleep Apnea (PR Newswire)
06.06.17	Jazz Pharmaceuticals Presents Data for the Phase 3 TONES 2 Study of JZP-110 in Patients with Excessive Sleepiness Associated with Narcolepsy (PR Newswire)
01.06.17	FDA Greenlights Novo Nordisk's Rebinyn, TEVA's HALO Shines, LUCY Walks The Talk (RTTNews)
31.05.17	Jazz Pharmaceuticals Announces FDA Acceptance of NDA for VYXEOS™ (CPX-351), an Investigational Treatment for Acute Myeloid Leukemia, with Priority Review Status (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Jazz Pharmaceuticals PLC

Aktien Top/Flop

Meistgelesene Nachrichten